Protect Patients. Preserve 340B.

Blog

More than 20 years ago, Congress created the 340B Drug Pricing Program to allow eligible hospitals and health systems to stretch limited resources and expand access to care for vulnerable patients. But despite a proven track record of increasing patient access to vital medical services and decreasing... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

AHA: Proposed 340B guidance would hurt hospitals' ability to serve patients

AHA News Now

The Health Resources and Services Administration’s proposed omnibus guidance for the 340B Drug Pricing Program would jeopardize hospitals’ ability to serve vulnerable populations, including low-income and uninsured individuals and patients receiving cancer treatments, AHA told the agency in ... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, Medicaid, drug prices

AHA: Proposed 340B guidance would hurt hospitals' ability to serve patients

AHA News

The Health Resources and Services Administration’s (HRSA) proposed omnibus guidance for the 340B Drug Pricing Program would jeopardize hospitals’ ability to serve vulnerable populations, including low-income and uninsured individuals and patients receiving cancer treatments, AHA told the agency in ... read more

Topic: Advocacy and Public Policy
Tag: 340B

340B Proposals Would Jeopardize Hospitals' Ability to Serve Vulnerable Patients

Blog

The 340B Drug Pricing Program has a strong track record of helping to combat high prescription drug prices and increase access to vital medicines and comprehensive health care services for our nation’s most vulnerable individuals.

However, we are concerned that recent policy changes proposed by the... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, drug prices

AHA op-ed: 340B program benefits patients, communities

AHA News Now

Congress should preserve the 340B Drug Pricing Program to protect access to life-saving medications and services for vulnerable hospital patients, AHA President and CEO Rick Pollack writes today in the Congress blog at The Hill. “The exorbitant cost of prescription drugs threatens access and affordability... read more

Topic: Advocacy and Public Policy
Tag: 340B

Court ruling on 340B drug case draws AHA's ire

AHA News

The AHA last week said it is “very disappointed” with a federal court decision that will exclude all drugs with an “orphan” designation from the 340B Drug Pricing Program for rural and cancer hospitals.

Denying rural and cancer hospitals access to these 340B discounts will “reduce access to critical... read more

Topics: Access and Coverage, Advocacy and Public Policy
Tags: 340B, access

AHA 'very disappointed' with court's ruling in 340B orphan drug case

AHA News Now

The AHA today expressed disappointment with a federal court decision that will exclude all drugs with an "orphan" designation from the 340B Drug Pricing Program for rural and cancer hospitals. AHA Executive Vice President Tom Nickels said in a statement that denying rural and cancer hospitals access to... read more

Topic: Advocacy and Public Policy
Tags: 340B, rural

AHA disappointed with court's ruling in 340B orphan drug case

AHA News

The AHA today expressed disappointment with a federal court decision that will exclude all drugs with an “orphan” designation from the 340B Drug Pricing Program for rural and cancer hospitals.

 AHA Executive Vice President Tom Nickels said in a statement that denying rural and cancer hospitals access to... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program

HRSA issues proposed guidance for 340B Drug Pricing Program

AHA News Now

The Health Resources and Services Administration today released proposed omnibus guidance for the 340B Drug Pricing Program in the form of a notice with a 60-day comment period. The guidance covers: covered entity eligibility; patient definition; Group Purchasing Organization prohibition; contract... read more

Topic: Advocacy and Public Policy
Tag: 340B

AHA: GAO report on 340B program misses the mark

AHA News Now

A July 6 Government Accountability Office report examining Medicare Part B spending at hospitals participating in the 340B Drug Pricing Program draws unsubstantiated conclusions about a program that has a proven track record of improving access to care for poor patients and vulnerable communities, ... read more

Topic: Advocacy and Public Policy
Tags: 340B, Medicare, advocacy

Keyword Search

Date